Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 3Lymphoid 3Myeloid 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma 1Leukemia 1

Interventions

Cyclophosphamide 125fludarabine phosphate 116Busulfan 98Peripheral Blood Stem Cell Transplantation 88Filgrastim 73Antilymphocyte Serum 72Tacrolimus 67Cytarabine 67Cyclosporine 64Mycophenolic Acid 63Methotrexate 57Radiotherapy 54fludarabine 52Whole-Body Irradiation 52Melphalan 49Imatinib Mesylate 41Azacitidine 35Methylprednisolone 34Etoposide 33Cord Blood Stem Cell Transplantation 30Granulocyte Colony-Stimulating Factor 28sargramostim 26Thiotepa 26Decitabine 21Alemtuzumab 21Clofarabine 20thymoglobulin 19Stem Cell Transplantation 19nilotinib 18Interferon-alpha 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × liposomal doxorubicin × Myeloid × Clear all
NCT00074490 2018-12-31

Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
442 enrolled 17 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡